Please Wait.....
Report
US AND Europe Diabetes Associated Eye Disorders Market Research Report Forecast to 2030
Market Report I 2023-12-24 I 122 Pages I Market Research Future
US AND Europe Diabetes Associated Eye Disorders Market Research Report Forecast to 2030
Market Overview
US AND Europe Diabetes Associated Eye Disorders Market is expected to register a notable CAGR of 6.46% during the review period. Diabetes-Associated Eye Disorders, also known as Diabetic Eye Diseases, refer to a group of eye conditions that can develop as complications of diabetes, particularly in individuals who have poorly managed blood sugar levels over an extended period.
The market growth is attributed to the rising prevalence of Diabetis, increasing awareness of opthalmic diseases, and growing government initiatives.
Market Segmentation
Based on disease type, the US and Europe diabetes associated eye disorders market has been bifurcated into diabetic retinopathy and Diabetic Macular Edema (DME). The diabetic retinopathy segment dominated the market in 2022, while the diabetic macular edema (DME) segment is projected to be the faster-growing segment during the forecast period, 2023-2032.
On the basis of diagnosis & treatment, the US and Europe diabetes associated eye disorders market is bifurcated into diagnosis and treatment. The treatment segment dominated the market in 2022, as well as treatment segment is projected to be the faster-growing segment during the forecast period, 2023-2032.
On the basis of end user, the US and Europe diabetes associated eye disorders market is segmented into hospitals & clinics, ophthalmic centers, and others. The hospitals & clinics segment dominated the market in 2022, while the ophthalmic centers segment is projected to be the fastest-growing segment during the forecast period, 2023-2032.
Regional Analysis
The report on the US and Europe diabetes associated eye disorders market has been segmented based on Country/ Region as US, Europe
The US dominated the market for diabetes associated eye disorders in 2022, accounting for the largest revenue share of 52.82%. Strong healthcare infrastructure, rising patient awareness of early disease diagnosis and treatment, supportive reimbursement policies, and the rising prevalence of diabetes are some of the main causes of the region's growth. Diabetes is on the rise in the United States at an alarming rate.
Government initiatives, an extensive number of R&D activities, and the improvement of healthcare providers' skill sets are factors that promote growth in the diabetes associated eye disorder market. When combined with patients' increasing awareness, it is anticipated that such supportive initiatives will result in profitable growth. By utilizing cutting-edge technology and using laser procedures with quick recoveries, the treatment of diabetic associated eye disorder market is anticipated to increase patient willingness for treatment.
Major Players
Thes include Novartis AG, Carl Zeiss Meditec AG, Alimera Sciences, Topcon Corporation, Bayer AG, and Regeneron Pharmaceuticals Inc.
TABLE OF CONTENTS
1 EXECUTIVE SUMMARY 17
2 MARKET INTRODUCTION 19
2.1 DEFINITION 19
2.2 SCOPE OF THE STUDY 19
2.3 RESEARCH OBJECTIVE 19
2.4 MARKET STRUCTURE 20
3 RESEARCH METHODOLOGY 21
3.1 INTRODUCTION 21
3.2 DATA FLOW 23
3.2.1 DATA MINING PROCESS 23
3.3 PURCHASED DATABASE: 24
3.4 SECONDARY SOURCES: 25
3.4.1 SECONDARY RESEARCH DATA FLOW: 26
3.5 PRIMARY RESEARCH: 27
3.5.1 PRIMARY RESEARCH DATA FLOW: 28
3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED 29
3.5.3 PRIMARY RESEARCH: REGIONAL COVERAGE Error! Bookmark not defined.
3.6 APPROACHES FOR MARKET SIZE ESTIMATION: 30
3.6.1 REVENUE ANALYSIS APPROACH 30
3.7 DATA FORECASTING 30
3.7.1 DATA FORECASTING TECHNIQUE 31
3.8 DATA MODELING 32
3.8.1 MICROECONOMIC FACTOR ANALYSIS: 32
3.8.2 DATA MODELING: 33
3.9 TEAMS AND ANALYST CONTRIBUTION 34
4 MARKET DYNAMICS 36
4.1 INTRODUCTION 36
4.2 DRIVERS 37
4.2.1 INCREASING PREVALENCE OF DIABETES 37
4.2.2 RISE IN GOVERNMENT INITIATIVES 37
4.3 RESTRAINTS 39
4.3.1 SIDE EFFECTS ASSOCIATED WITH TREATMENTS 39
4.4 OPPORTUNITY 40
4.4.1 GROWING NUMBER OF KEY PLAYERS AND APPROVAL OF TREATMENT 40
5 MARKET FACTOR ANALYSIS 41
5.1 VALUE CHAIN ANALYSIS 41
5.1.1 R&D 42
5.1.2 MANUFACTURING 42
5.1.3 DISTRIBUTION AND SALES 42
5.1.4 POST-SALES MONITORING 42
5.2 PORTER'S FIVE FORCES MODEL 43
5.2.1 THREAT OF NEW ENTRANTS 43
5.2.2 BARGAINING POWER OF SUPPLIERS 44
5.2.3 THREAT OF SUBSTITUTES 44
5.2.4 BARGAINING POWER OF BUYERS 44
5.2.5 INTENSITY OF RIVALRY 44
5.3 COVID-19 IMPACT ANALYSIS 45
5.3.1 OVERVIEW 45
5.4 PREMIUM INSIGHTS 46
5.4.1 ANTI-VEGF FAILURES 46
5.4.2 IMPACT OF AI IN RETINAL SCREENING 46
5.4.3 LIMITATIONS DUE TO DEARTH OF OPHTHALMOLOGY MD SPECIALISTS 47
6 US AND EU DIABETES ASSOCIATED EYE DISORDERS MARKET, BY DISEASE TYPE 49
6.1 INTRODUCTION 49
6.2 DIABETIC RETINOPATHY 51
6.2.1 MILD NONPROLIFERATIVE STAGE 52
6.2.2 MODERATE NONPROLIFERATIVE STAGE 52
6.2.3 SEVERE NONPROLIFERATIVE STAGE 52
6.2.4 PROLIFERATIVE DIABETIC 53
6.3 DIABETIC MACULAR EDEMA (DME) 53
7 US AND EU DIABETES ASSOCIATED EYE DISORDERS MARKET, BY DISEASE & TREATMENT 54
7.1 INTRODUCTION 54
7.2 DIAGNOSIS 56
7.2.1 FLUORESCEIN ANGIOGRAPHY 57
7.2.2 OPTICAL COHERENCE TOMOGRAPHY (OCT) 57
7.2.3 OPHTHALMOSCOPY 58
7.2.4 SLIT LAMP BIOMICROSCOPY 58
7.2.5 OTHERS 58
7.3 TREATMENT 59
7.3.1 ANTI-VEGF 59
7.3.2 INTRAOCULAR STEROID INJECTION 60
7.3.3 LASER SURGERY 60
7.3.4 VITRECTOMY 60
8 US AND EU DIABETES ASSOCIATED EYE DISORDERS MARKET, BY END USER 61
8.1 INTRODUCTION 61
8.2 HOSPITAL & CLINICS 63
8.3 OPHTHALMIC CENTERS 63
8.4 OTHERS 63
9 US AND EU DIABETES ASSOCIATED EYE DISORDERS MARKET, BY REGION 64
9.1 INTRODUCTION 64
9.2 US 65
9.3 EUROPE 68
9.3.1 GERMANY 72
9.3.2 FRANCE 74
9.3.3 UK 76
9.3.4 ITALY 78
9.3.5 SPAIN 80
9.3.6 REST OF EUROPE 82
10 COMPETITIVE LANDSCAPE 85
10.1 INTRODUCTION 85
10.2 MARKET SHARE ANALYSIS, 2022 85
10.3 COMPETITOR DASHBOARD 86
10.4 PUBLIC PLAYERS STOCK SUMMARY 87
10.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL 87
10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES 88
10.6.1 PRODUCT LAUNCH/PRODUCT APPROVAL 88
10.6.2 MERGER AND ACQUISITION 88
10.6.3 PARTNERSHIP/INVESTMENT 89
11 COMPANY PROFILES 90
11.1 NOVARTIS AG 90
11.1.1 COMPANY OVERVIEW 90
11.1.2 FINANCIAL OVERVIEW 91
11.1.3 PRODUCTS OFFERED 91
11.1.4 KEY DEVELOPMENTS 92
11.1.5 SWOT ANALYSIS 92
11.1.6 KEY STRATEGY 92
11.2 GENENTECH, INC. 93
11.2.1 COMPANY OVERVIEW 93
11.2.2 FINANCIAL OVERVIEW 93
11.2.3 PRODUCTS OFFERED 93
11.2.4 KEY DEVELOPMENTS 94
11.2.5 SWOT ANALYSIS 94
11.2.6 KEY STRATEGY 94
11.3 CARL ZEISS MEDITEC AG 95
11.3.1 COMPANY OVERVIEW 95
11.3.2 FINANCIAL OVERVIEW 96
11.3.3 PRODUCTS OFFERED 96
11.3.4 KEY DEVELOPMENTS 97
11.3.5 SWOT ANALYSIS 98
11.3.6 KEY STRATEGIES 98
11.4 DIGITAL DIAGNOSTICS, INC. 99
11.4.1 COMPANY OVERVIEW 99
11.4.2 FINANCIAL OVERVIEW 99
11.4.3 PRODUCTS OFFERED 99
11.4.4 KEY DEVELOPMENTS 100
11.4.5 KEY STRATEGIES 100
11.5 BAYER AG 101
11.5.1 COMPANY OVERVIEW 101
11.5.2 FINANCIAL OVERVIEW 102
11.5.3 PRODUCTS OFFERED 102
11.5.4 KEY DEVELOPMENTS 102
11.5.5 SWOT ANALYSIS 103
11.5.6 KEY STRATEGIES 103
11.6 REGENERON PHARMACEUTICALS INC 104
11.6.1 COMPANY OVERVIEW 104
11.6.2 FINANCIAL OVERVIEW 105
11.6.3 PRODUCTS OFFERED 105
11.6.4 KEY DEVELOPMENTS 106
11.6.5 SWOT ANALYSIS 106
11.6.6 KEY STRATEGIES 107
11.7 AMPIO PHARMACEUTICALS INC 108
11.7.1 COMPANY OVERVIEW 108
11.7.2 FINANCIAL OVERVIEW 108
11.7.3 PRODUCTS OFFERED 108
11.7.4 KEY DEVELOPMENTS 109
11.7.5 KEY STRATEGIES 109
11.8 TOPCON CORPORATION 110
11.8.1 COMPANY OVERVIEW 110
11.8.2 FINANCIAL OVERVIEW 111
11.8.3 DISEASE TYPES OFFERED 112
11.8.4 KEY DEVELOPMENTS 112
11.8.5 SWOT ANALYSIS 113
11.8.6 KEY STRATEGY 113
11.9 ALIMERA SCIENCES 114
11.9.1 COMPANY OVERVIEW 114
11.9.2 FINANCIAL OVERVIEW 115
11.9.3 PRODUCTS OFFERED 115
11.9.4 KEY DEVELOPMENTS 116
11.9.5 KEY STRATEGY 116
11.10 GEUDER AG 117
11.10.1 COMPANY OVERVIEW 117
11.10.2 FINANCIAL OVERVIEW 117
11.10.3 PRODUCTS OFFERED 117
11.10.4 KEY DEVELOPMENTS 118
11.10.5 KEY STRATEGY 118
12 DATA CITATIONS 119
?
LIST OF TABLES
TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT 33
TABLE 2 US AND EUROPE: DIABETIC ASSOCIATED EYE DISORDERS MARKET, BY DISEASE TYPE, 2019-2032 (USD MILLION) 51
TABLE 3 US AND EUROPE: DIABETIC ASSOCIATED EYE DISORDERS MARKET, FOR DIABETIC RETINOPATHY, BY REGION, 2019-2032 (USD MILLION) 51
TABLE 4 US AND EUROPE: DIABETIC ASSOCIATED EYE DISORDERS MARKET, FOR DIABETIC RETINOPATHY, BY TYPE, 2019-2032 (USD MILLION) 51
TABLE 5 US AND EUROPE: DIABETIC ASSOCIATED EYE DISORDERS MARKET, FOR MILD NONPROLIFERATIVE STAGE, BY REGION, 2019-2032 (USD MILLION) 52
TABLE 6 US AND EUROPE: DIABETIC ASSOCIATED EYE DISORDERS MARKET, FOR MODERATE NONPROLIFERATIVE STAGE, BY REGION, 2019-2032 (USD MILLION) 52
TABLE 7 US AND EUROPE: DIABETIC ASSOCIATED EYE DISORDERS MARKET, FOR SEVERE NONPROLIFERATIVE STAGE, BY REGION, 2019-2032 (USD MILLION) 52
TABLE 8 US AND EUROPE: DIABETIC ASSOCIATED EYE DISORDERS MARKET, FOR PROLIFERATIVE DIABETIC, BY REGION, 2019-2032 (USD MILLION) 53
TABLE 9 US AND EUROPE: DIABETIC ASSOCIATED EYE DISORDERS MARKET, FOR DIABETIC MACULAR EDEMA (DME), BY REGION, 2019-2032 (USD MILLION) 53
TABLE 10 US AND EUROPE: DIABETIC ASSOCIATED EYE DISORDERS MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MILLION) 56
TABLE 11 US AND EUROPE: DIABETIC ASSOCIATED EYE DISORDERS MARKET, FOR DIAGNOSIS, BY REGION, 2019-2032 (USD MILLION) 56
TABLE 12 US AND EUROPE: DIABETIC ASSOCIATED EYE DISORDERS MARKET, FOR DIAGNOSIS, BY TYPE, 2019-2032 (USD MILLION) 57
TABLE 13 US AND EUROPE: DIABETIC ASSOCIATED EYE DISORDERS MARKET, FOR FLUORESCEIN ANGIOGRAPHY, BY REGION, 2019-2032 (USD MILLION) 57
TABLE 14 US AND EUROPE: DIABETIC ASSOCIATED EYE DISORDERS MARKET, FOR OPTICAL COHERENCE TOMOGRAPHY (OCT), BY REGION, 2019-2032 (USD MILLION) 57
TABLE 15 US AND EUROPE: DIABETIC ASSOCIATED EYE DISORDERS MARKET, FOR OPHTHALMOSCOPY, BY REGION, 2019-2032 (USD MILLION) 58
TABLE 16 US AND EUROPE: DIABETIC ASSOCIATED EYE DISORDERS MARKET, FOR SLIT LAMP BIOMICROSCOPY, BY REGION, 2019-2032 (USD MILLION) 58
TABLE 17 US AND EUROPE: DIABETIC ASSOCIATED EYE DISORDERS MARKET, FOR OTHERS, BY REGION, 2019-2032 (USD MILLION) 58
TABLE 18 US AND EUROPE: DIABETIC ASSOCIATED EYE DISORDERS MARKET, FOR TREATMENT, BY REGION, 2019-2032 (USD MILLION) 59
TABLE 19 US AND EUROPE: DIABETIC ASSOCIATED EYE DISORDERS MARKET, FOR TREATMENT, BY TYPE, 2019-2032 (USD MILLION) 59
TABLE 20 US AND EUROPE: DIABETIC ASSOCIATED EYE DISORDERS MARKET, FOR ANTI-VEGF, BY REGION, 2019-2032 (USD MILLION) 59
TABLE 21 US AND EUROPE: DIABETIC ASSOCIATED EYE DISORDERS MARKET, FOR INTRAOCULAR STEROID INJECTION, BY REGION, 2019-2032 (USD MILLION) 60
TABLE 22 US AND EUROPE: DIABETIC ASSOCIATED EYE DISORDERS MARKET, FOR LASER SURGERY, BY REGION, 2019-2032 (USD MILLION) 60
TABLE 23 US AND EUROPE: DIABETIC ASSOCIATED EYE DISORDERS MARKET, FOR VITRECTOMY, BY REGION, 2019-2032 (USD MILLION) 60
TABLE 24 US AND EUROPE: DIABETIC ASSOCIATED EYE DISORDERS MARKET, BY END USER, 2019-2032 (USD MILLION) 62
TABLE 25 US AND EUROPE: DIABETIC ASSOCIATED EYE DISORDERS MARKET, FOR HOSPITAL & CLINICS, BY REGION, 2019-2032 (USD MILLION) 63
TABLE 26 US AND EUROPE: DIABETIC ASSOCIATED EYE DISORDERS MARKET, FOR OPHTHALMIC CENTERS, BY REGION, 2019-2032 (USD MILLION) 63
TABLE 27 US AND EUROPE: DIABETIC ASSOCIATED EYE DISORDERS MARKET, FOR OTHERS, BY REGION, 2019-2032 (USD MILLION) 63
TABLE 28 US AND EUROPE DIABETIC ASSOCIATED EYE DISORDER MARKET, BY REGION, 2019-2032 (USD MILLION) 65
TABLE 29 US: DIABETES ASSOCIATED EYE DISORDERS MARKET, BY DISEASE TYPE, 2019-2032 (USD MILLION) 66
TABLE 30 US: DIABETES ASSOCIATED EYE DISORDERS MARKET, FOR DIABETIC RETINOPATHY, BY TYPE, 2019-2032 (USD MILLION) 66
TABLE 31 US: DIABETES ASSOCIATED EYE DISORDERS MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MILLION) 66
TABLE 32 US: DIABETES ASSOCIATED EYE DISORDERS MARKET, FOR DIAGNOSIS, BY TYPE, 2019-2032 (USD MILLION) 67
TABLE 33 US: DIABETES ASSOCIATED EYE DISORDERS MARKET, FOR TREATMENT, BY TYPE, 2019-2032 (USD MILLION) 67
TABLE 34 US: DIABETES ASSOCIATED EYE DISORDERS MARKET, BY END USER 2019-2032 (USD MILLION) 67
TABLE 35 EUROPE: DIABETES ASSOCIATED EYE DISORDERS MARKET, BY COUNTRY, 2019-2032 (USD MILLION) 69
TABLE 36 EUROPE: DIABETES ASSOCIATED EYE DISORDERS MARKET, BY DISEASE TYPE, 2019-2032 (USD MILLION) 70
TABLE 37 EUROPE: DIABETES ASSOCIATED EYE DISORDERS MARKET, FOR DIABETIC RETINOPATHY, BY TYPE, 2019-2032 (USD MILLION) 70
TABLE 38 EUROPE: DIABETES ASSOCIATED EYE DISORDERS MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MILLION) 70
TABLE 39 EUROPE: DIABETES ASSOCIATED EYE DISORDERS MARKET, FOR DIAGNOSIS, BY TYPE, 2019-2032 (USD MILLION) 71
TABLE 40 EUROPE: DIABETES ASSOCIATED EYE DISORDERS MARKET, FOR TREATMENT, BY TYPE, 2019-2032 (USD MILLION) 71
TABLE 41 EUROPE: DIABETES ASSOCIATED EYE DISORDERS MARKET, BY END USER, 2019-2032 (USD MILLION) 71
TABLE 42 GERMANY: DIABETES ASSOCIATED EYE DISORDERS MARKET, BY DISEASE TYPE, 2019-2032 (USD MILLION) 72
TABLE 43 GERMANY: DIABETES ASSOCIATED EYE DISORDERS MARKET, FOR DIABETIC RETINOPATHY, BY TYPE, 2019-2032 (USD MILLION) 72
TABLE 44 GERMANY: DIABETES ASSOCIATED EYE DISORDERS MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MILLION) 72
TABLE 45 GERMANY: DIABETES ASSOCIATED EYE DISORDERS MARKET, FOR DIAGNOSIS, BY TYPE, 2019-2032 (USD MILLION) 73
TABLE 46 GERMANY: DIABETES ASSOCIATED EYE DISORDERS MARKET, FOR TREATMENT, BY TYPE, 2019-2032 (USD MILLION) 73
TABLE 47 GERMANY: DIABETES ASSOCIATED EYE DISORDERS MARKET, BY END USER, 2019-2032 (USD MILLION) 73
TABLE 48 FRANCE: DIABETES ASSOCIATED EYE DISORDERS MARKET, BY DISEASE TYPE, 2019-2032 (USD MILLION) 74
TABLE 49 FRANCE: DIABETES ASSOCIATED EYE DISORDERS MARKET, FOR DIABETIC RETINOPATHY, BY TYPE, 2019-2032 (USD MILLION) 74
TABLE 50 FRANCE: DIABETES ASSOCIATED EYE DISORDERS MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MILLION) 74
TABLE 51 FRANCE: DIABETES ASSOCIATED EYE DISORDERS MARKET, FOR DIAGNOSIS, BY TYPE, 2019-2032 (USD MILLION) 75
TABLE 52 FRANCE: DIABETES ASSOCIATED EYE DISORDERS MARKET, FOR TREATMENT, BY TYPE, 2019-2032 (USD MILLION) 75
TABLE 53 FRANCE: DIABETES ASSOCIATED EYE DISORDERS MARKET, BY END USER, 2019-2032 (USD MILLION) 75
TABLE 54 UK: DIABETES ASSOCIATED EYE DISORDERS MARKET, BY DISEASE TYPE, 2019-2032 (USD MILLION) 76
TABLE 55 UK: DIABETES ASSOCIATED EYE DISORDERS MARKET, FOR DIABETIC RETINOPATHY, BY TYPE, 2019-2032 (USD MILLION) 76
TABLE 56 UK: DIABETES ASSOCIATED EYE DISORDERS MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MILLION) 76
TABLE 57 UK: DIABETES ASSOCIATED EYE DISORDERS MARKET, FOR DIAGNOSIS, BY TYPE, 2019-2032 (USD MILLION) 77
TABLE 58 UK: DIABETES ASSOCIATED EYE DISORDERS MARKET, FOR TREATMENT, BY TYPE, 2019-2032 (USD MILLION) 77
TABLE 59 UK: DIABETES ASSOCIATED EYE DISORDERS MARKET, BY END USER, 2019-2032 (USD MILLION) 77
TABLE 60 ITALY: DIABETES ASSOCIATED EYE DISORDERS MARKET, BY DISEASE TYPE, 2019-2032 (USD MILLION) 78
TABLE 61 ITALY: DIABETES ASSOCIATED EYE DISORDERS MARKET, FOR DIABETIC RETINOPATHY, BY TYPE, 2019-2032 (USD MILLION) 78
TABLE 62 ITALY: DIABETES ASSOCIATED EYE DISORDERS MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MILLION) 78
TABLE 63 ITALY: DIABETES ASSOCIATED EYE DISORDERS MARKET, FOR DIAGNOSIS, BY TYPE, 2019-2032 (USD MILLION) 79
TABLE 64 ITALY: DIABETES ASSOCIATED EYE DISORDERS MARKET, FOR TREATMENT, BY TYPE, 2019-2032 (USD MILLION) 79
TABLE 65 ITALY: DIABETES ASSOCIATED EYE DISORDERS MARKET, BY END USER, 2019-2032 (USD MILLION) 79
TABLE 66 SPAIN: DIABETES ASSOCIATED EYE DISORDERS MARKET, BY DISEASE TYPE, 2019-2032 (USD MILLION) 80
TABLE 67 SPAIN: DIABETES ASSOCIATED EYE DISORDERS MARKET, FOR DIABETIC RETINOPATHY, BY TYPE, 2019-2032 (USD MILLION) 80
TABLE 68 SPAIN: DIABETES ASSOCIATED EYE DISORDERS MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MILLION) 80
TABLE 69 SPAIN: DIABETES ASSOCIATED EYE DISORDERS MARKET, FOR DIAGNOSIS, BY TYPE, 2019-2032 (USD MILLION) 81
TABLE 70 SPAIN: DIABETES ASSOCIATED EYE DISORDERS MARKET, FOR TREATMENT, BY TYPE, 2019-2032 (USD MILLION) 81
TABLE 71 SPAIN: DIABETES ASSOCIATED EYE DISORDERS MARKET, BY END USER, 2019-2032 (USD MILLION) 81
TABLE 72 REST OF EUROPE: DIABETES ASSOCIATED EYE DISORDERS MARKET, BY DISEASE TYPE, 2019-2032 (USD MILLION) 82
TABLE 73 REST OF EUROPE: DIABETES ASSOCIATED EYE DISORDERS MARKET, FOR DIABETIC RETINOPATHY, BY TYPE, 2019-2032 (USD MILLION) 82
TABLE 74 REST OF EUROPE: DIABETES ASSOCIATED EYE DISORDERS MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MILLION) 82
TABLE 75 REST OF EUROPE: DIABETES ASSOCIATED EYE DISORDERS MARKET, FOR DIAGNOSIS, BY TYPE, 2019-2032 (USD MILLION) 83
TABLE 76 REST OF EUROPE: DIABETES ASSOCIATED EYE DISORDERS MARKET, FOR TREATMENT, BY TYPE, 2019-2032 (USD MILLION) 83
TABLE 77 REST OF EUROPE: DIABETES ASSOCIATED EYE DISORDERS MARKET, BY END USER, 2019-2032 (USD MILLION) 83
TABLE 78 PUBLIC PLAYERS STOCK SUMMARY 87
TABLE 79 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL 87
TABLE 80 PRODUCT LAUNCH/PRODUCT APPROVAL 88
TABLE 81 MERGER AND ACQUISITION 88
TABLE 82 PARTNERSHIP/INVESTMENT 89
TABLE 83 NOVARTIS AG: PRODCUTS OFFERED 91
TABLE 84 NOVARTIS AG: KEY DEVELOPMENTS 92
TABLE 85 GENENTECH, INC.: PRODUCTS OFFERED 93
TABLE 86 GENENTECH, INC.: KEY DEVELOPMENTS 94
TABLE 87 CARL ZEISS MEDITEC AG: PRODUCTS OFFERED 96
TABLE 88 CARL ZEISS MEDITEC AG: KEY DEVELOPMENTS 97
TABLE 89 DIGITAL DIAGNOSTICS, INC. : PRODUCTS OFFERED 99
TABLE 90 DIGITAL DIAGNOSTICS, INC. : KEY DEVELOPMENTS 100
TABLE 91 BAYER AG: PRODCUTS OFFERED 102
TABLE 92 REGENERON PHARMACEUTICALS INC: PRODCUTS OFFERED 105
TABLE 93 REGENERON PHARMACEUTICALS INC: KEY DEVELOPMENTS 106
TABLE 94 AMPIO PHARMACEUTICALS INC: PRODCUTS OFFERED 108
TABLE 95 TOPCON CORPORATION: DISEASE TREATMENT OFFERED 112
TABLE 96 TOPCON CORPORATION: KEY DEVELOPMENTS 112
TABLE 97 ALIMERA SCIENCES: PRODCUTS OFFERED 115
TABLE 98 ALIMERA SCIENCES: KEY DEVELOPMENTS 116
TABLE 99 GEUDER AG: PRODCUTS OFFERED 117
?
LIST OF FIGURES
FIGURE 1 US AND EU DIABETES ASSOCIATED EYE DISORDERS MARKET: STRUCTURE 20
FIGURE 2 US AND EU DIABETES ASSOCIATED EYE DISORDERS MARKET: MARKET GROWTH FACTOR ANALYSIS (2022-2032) 36
FIGURE 3 DRIVER IMPACT ANALYSIS (2023-2032) 38
FIGURE 4 RESTRAINT IMPACT ANALYSIS (2022-2032) 39
FIGURE 5 OPPORTUNITY IMPACT FORECAST 40
FIGURE 6 VALUE CHAIN ANALYSIS: US AND EUROPE DIABETES ASSOCIATED EYE DISORDERS MARKET 41
FIGURE 7 PORTER'S FIVE FORCES MODEL: US AND EUROPE DIABETES ASSOCIATED EYE DISORDERS MARKET 43
FIGURE 8 US AND EUROPE DIABETES ASSOCIATED EYE DISORDERS MARKET; DISEASE TYPE SEGMENT ATTRACTIVENESS, (USD MILLION) 49
FIGURE 9 US AND EUROPE DIABETIC ASSOCIATED EYE DISORDERS MARKET, BY DISEASE TYPE, 2022 & 2032 (USD MILLION) 50
FIGURE 10 US AND EUROPE DIABETES ASSOCIATED EYE DISORDERS MARKET; DIAGNOSIS & TREATMENT SEGMENT ATTRACTIVENESS,
(USD MILLION) 55
FIGURE 11 US AND EUROPE DIABETIC ASSOCIATED EYE DISORDERS MARKET, BY DIAGNOSIS & TREATMENT, 2022 & 2032 (USD MILLION) 55
FIGURE 12 US AND EUROPE DIABETES ASSOCIATED EYE DISORDERS MARKET; END USER SEGMENT ATTRACTIVENESS, (USD MILLION) 61
FIGURE 13 US AND EUROPE DIABETIC ASSOCIATED EYE DISORDERS MARKET, BY END USER, 2022 & 2032 (USD MILLION) 62
FIGURE 14 US AND EUROPE DIABETIC ASSOCIATED EYE DISORDER MARKET SHARE, BY REGION, 2022 (% SHARE) 64
FIGURE 15 US AND EUROPE DIABETIC ASSOCIATED EYE DISORDER MARKET, BY REGION, 2022 & 2030 (USD MILLION) 64
FIGURE 16 US MARKET ANALYSIS: DIABETES ASSOCIATED EYE DISORDERS MARKET, 2019-2023(USD MILLION) 65
FIGURE 17 EUROPE MARKET ANALYSIS: DIABETES ASSOCIATED EYE DISORDERS MARKET, 2019-2023 (USD MILLION) 68
FIGURE 18 EUROPE: DIABETES ASSOCIATED EYE DISORDERS MARKET SHARE, BY COUNTRY, 2022 (% SHARE) 69
FIGURE 19 EUROPE: DIABETES ASSOCIATED EYE DISORDERS MARKET, BY COUNTRY, 2022 & 2030 (USD MILLION) 69
FIGURE 20 US AND EU DIABETES ASSOCIATED EYE DISORDERS PLAYERS: COMPETITIVE ANALSIS, 2022 85
FIGURE 21 COMPETITOR DASHBOARD: US AND EU DIABETES ASSOCIATED EYE DISORDERS 86
FIGURE 22 NOVARTIS AG: FINANCIAL OVERVIEW SNAPSHOT 91
FIGURE 23 NOVARTIS AG: SWOT ANALYSIS 92
FIGURE 24 GENENTECH, INC.: SWOT ANALYSIS 94
FIGURE 25 CARL ZEISS MEDITEC AG: FINANCIAL OVERVIEW SNAPSHOT 96
FIGURE 26 CARL ZEISS MEDITEC AG: SWOT ANALYSIS 98
FIGURE 27 BAYER AG: FINANCIAL OVERVIEW SNAPSHOT 102
FIGURE 28 BAYER AG: SWOT ANALYSIS 103
FIGURE 29 REGENERON PHARMACEUTICALS INC: FINANCIAL OVERVIEW SNAPSHOT 105
FIGURE 30 REGENERON PHARMACEUTICALS INC: SWOT ANALYSIS 106
FIGURE 31 TOPCON CORPORATION: FINANCIAL OVERVIEW SNAPSHOT 111
FIGURE 32 TOPCON CORPORATION: SWOT ANALYSIS 113
FIGURE 33 ALIMERA SCIENCES: FINANCIAL OVERVIEW SNAPSHOT 115
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security